Inhibition of miR-146b-5p alleviates isoprenaline-induced cardiac hypertrophy via regulating DFCP1
Molecular and Cellular Endocrinology · 2024
DOI: 10.1016/j.mce.2024.112252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular and Cellular Endocrinology, 2024. Verfasst von Siling Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Sun Yat-Sen University, National and Local United Engineering Lab of Druggability and New Drugs Evaluation, Guangd…. Hauptthemen laut MEDLINE: MicroRNAs, Isoproterenol, Cardiomegaly, Myocytes, Cardiac. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Pathological cardiac hypertrophy often precedes heart failure due to various stimuli, yet effective clinical interventions remain limited. Recently, microRNAs (miRNAs) have been identified as critical regulators of cardiovascular development. In this study, we investigated the role of miR-146b-5p and its underlying mechanisms of action in cardiac hypertrophy. Isoprenaline (ISO) treatment induced significant hypertrophy and markedly enhanced the expression of miR-146b-5p in cultured neonatal rat cardiomyocytes and hearts of C57BL/6 mice. Transfection with the miR-146b-5p mimic led to cardiomyocyte hypertrophy accompanied by autophagy inhibition. Conversely, miR-146b-5p inhibition significantly alleviated ISO-induced autophagy depression, thereby mitigating cardiac hypertrophy both in vitro and in vivo. Our results showed that the autophagy-related mediator double FYVE domain-containing protein 1 (DFCP1) is a target of miR-146b-5p. MiR-146b-5p blocked autophagic flux in cardiomyocytes by suppressing DFCP1, thus contributing to hypertrophy. These findings revealed that miR-146b-5p is a potential regulator of autophagy associated with the onset of cardiac hypertrophy, suggesting a possible therapeutic strategy involving the inhibition of miR-146b-5p.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmaceutical Sciences, Sun Yat-Sen University, National and Local United Engineering Lab of Druggability and New Drugs Evaluation, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, China.
- School of Pharmaceutical Sciences, Sun Yat-Sen University, National and Local United Engineering Lab of Druggability and New Drugs Evaluation, Guangdong Provincial Key Laboratory of New Drug Design and Evaluation, China…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, S., Su, L., Li, J., Zhang, Y., Hu, X., Wang, P., Liu, P., & Ye, J. (2024). Inhibition of miR-146b-5p alleviates isoprenaline-induced cardiac hypertrophy via regulating DFCP1. Molecular and Cellular Endocrinology. https://doi.org/10.1016/j.mce.2024.112252
Vancouver
Liu S, Su L, Li J, Zhang Y, Hu X, Wang P, et al. Inhibition of miR-146b-5p alleviates isoprenaline-induced cardiac hypertrophy via regulating DFCP1. Molecular and Cellular Endocrinology. 2024. doi:10.1016/j.mce.2024.112252
BibTeX
@article{Liu2024,
author = {Liu, Siling and Su, Linjie and Li, Jie and Zhang, Yuexin and Hu, Xiaopei and Wang, Pengcheng and Liu, Peiqing and Ye, Jiantao},
title = {Inhibition of miR-146b-5p alleviates isoprenaline-induced cardiac hypertrophy via regulating DFCP1},
journal = {Molecular and Cellular Endocrinology},
year = {2024},
doi = {10.1016/j.mce.2024.112252}
}
EUVIMED